Premenstrual syndrome and premenstrual disorders: principles of diagnosis and correction
https://doi.org/10.33667/2078-5631-2022-24-20-26
Abstract
Premenstrual syndrome is a term that combines several disorders that are different in pathogenesis and severity of treatment. Among them: the main premenstrual disorder, premenstrual exacerbation of another disease, and others. Premenstrual dysphoric disorder is actually a separate disorder that requires mental health care. This review presents the modern classification of these disorders, provides detailed guidance on their diagnosis and correction. Particular attention is paid to the role of combined oral contraception with drospirenone (COC-DRSP). This form of therapy corrects the symptoms of premenstrual disorders, regardless of the depth of the diagnosis, and is suitable for a significant number of women.
About the Author
D. I. Burchakov
Non-state educational private institution of additional professional education ‘Higher Medical School’
Russian Federation
Russian Federation
Burchakov Denis I., PhD Med, endocrinologist, associate professor at Dept of Endocrinology
Moscow
References
1. Zhilyaeva T. V. Premenstrual mood disorders: etiology, pathogenesis, diagnosis and treatment. Problemy Reproductions 2015.
2. Crowley T., Cryan J. F., Downer E. J., O’Leary O. F. Inhibiting Neuroinflammation: The Role and Therapeutic Potential of GABA in Neuro-Immune Interactions. Brain Behav. Immun. 2016, 54, 260–277.
3. Wu C., Qin X., Du H., Li N., Ren W., Peng Y. The Immunological Function of GABAergic System. Front. Biosci. 2017, 22, 1162–1172.
4. Ossewaarde L., Hermans E. J., van Wingen G. A., Kooijman S. C., Johansson I.-M., Bäckström T., Fernández G. Neural Mechanisms Underlying Changes in Stress-Sensitivity across the Menstrual Cycle. Psychoneuroendocrinology 2010, 35, 47–55.
5. Bäckström T., Haage D., Löfgren M., Johansson I. M., Strömberg J., Nyberg S., Andréen L., Ossewaarde L., van Wingen G. A., Turkmen S. et al. Paradoxical Effects of GABA-A Modulators May Explain Sex Steroid Induced Negative Mood Symptoms in Some Persons. Neuroscience 2011, 191, 46–54.
6. Bannister E. There Is Increasing Evidence to Suggest That Brain Inflammation Could Play a Key Role in the Aetiology of Psychiatric Illness. Could Inflammation Be a Cause of the Premenstrual Syndromes PMS and PMDD? Post Reprod Health 2019, 25, 157–161.
7. Endicott J., Nee J., Harrison W. Daily Record of Severity of Problems (DRSP): Reliability and Validity. Arch. Womens. Ment. Health 2006, 9, 41–49.
8. Nakajima S. T., Brumsted J. R., Riddick D. H., Gibson M. Absence of Progestational Activity of Oral Spironolactone. Fertil. Steril. 1989, 52, 155–158.
9. Genazzani A. R., Mannella P., Simoncini T. Drospirenone and Its Antialdosterone Properties. Climacteric 2007, 10 Suppl 1, 11–18.
10. de Nadai M. N., Nobre F., Ferriani R. A., Vieira C. S. Effects of Two Contraceptives Containing Drospirenone on Blood Pressure in Normotensive Women: A RandomizedControlled Trial. Blood Press. Monit. 2015, 20, 310–315.
11. Cagnacci A., Ferrari S., Napolitano A., Piacenti I., Arangino S., Volpe A. Combined Oral Contraceptive Containing Drospirenone Does Not Modify 24-H Ambulatory Blood Pressure but Increases Heart Rate in Healthy Young Women: Prospective Study. Contraception 2013, 88, 413–417.
12. de Morais T. L., Giribela C., Nisenbaum M. G., Guerra G., Mello N., Baracat E., Consolim-Colombo F. M. Effects of a Contraceptive Containing Drospirenone and Ethinylestradiol on Blood Pressure, Metabolic Profile and Neurohumoral Axis in Hypertensive Women at Reproductive Age. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014, 182, 113–117.
13. El Amki M., Binder N., Steffen R., Schneider H., Luft A. R., Weller M., Imthurn B., Merki-Feld G.S., Wegener S. Contraceptive Drugs Mitigate Experimental Stroke-Induced Brain Injury. Cardiovasc. Res. 2019, 115, 637–646.
14. Lopez L. M., Kaptein A. A., Helmerhorst F. M. Oral Contraceptives Containing Drospirenone for Premenstrual Syndrome. Cochrane Database Syst. Rev. 2012, CD 006586.
15. Wichianpitaya J., Taneepanichskul S. A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms. Obstet. Gynecol. Int. 2013, 2013, 487143.
16. Khadzhieva N. Kh., Kuznetsova I. V. Possibilities of COC-DRSP in women with stress-related menstrual disorders. Medical alphabet. 2021, 26, 23–27.
17. Tikhomirov A. L. Compliance with KOC: an affordable improvement in the quality of life. Gynecology.
Review
For citations:
Burchakov D.I. Premenstrual syndrome and premenstrual disorders: principles of diagnosis and correction. Medical alphabet. 2022;(24):20-26. (In Russ.) https://doi.org/10.33667/2078-5631-2022-24-20-26
Views:
357
Email this article 